The Readout Loud
262: Merck v. USA, the best of ASCO, and Leqembi at the FDA
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
STAT Washington correspondent Rachel Cohrs joins us to explain Merck's lawsuit against the federal government and why the company believes drug pricing negotiation is “tantamount to extortion." We also discuss the health effects of Canadian wildfires, the highlights of the year’s biggest cancer research conference, and what could be a watershed moment in the treatment of Alzheimer’s.